Over 3 million United States citizens are living with chronic hepatitis C. Hence, physicians specializing in infectious diseases and hepatology have been working toward a cure for the condition. Research physician Robert Hindes, MD, has been involved with clinical development of antiviral drugs that have resulted in breakthroughs in drug therapies for Hepatitis C.
This objective was the subject of a 2011 presentation by Robert Hindes, MD, regarding the use of nucleotide analogs in a new medicine known as GS-7977 (sofosbuvir). A nucleotide analog is an antiviral drug that is modified in such a way as to mimic the natural function of a nucleotide, which is a structural molecule in DNA. Unlike treatments for the hepatitis B virus, HIV, and herpes, results of clinical trials have demonstrated that with this kind of drug therapy, the hepatitis C virus is not just suppressed, but eradicated. The result is a steady reduction of the virus in the body until, optimally, it is no longer present.